Ralaniten
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed. It was codiscovered by Dr. Marianne D Sadar and Dr. Raymond J Andersen . It is a derivative of bisphenol A and one of the four stereoisomers of EPI-001. It comprises a new pharmacological class recognized by United States Adopted Names (USAN) Council called antigens which are defined as a drug designed to bind to the androgen receptor N-terminal domain. A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.
Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed. It was codiscovered by Dr. Marianne D Sadar and Dr. Raymond J Andersen . It is a derivative of bisphenol A and one of the four stereoisomers of EPI-001. It comprises a new pharmacological class recognized by United States Adopted Names (USAN) Council called antigens which are defined as a drug designed to bind to the androgen receptor N-terminal domain. A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1376503894 under CC BY-SA 4.0; modifications have been made.